Eli Lilly and Company (NYSE:LLY) Stock Holdings Lifted by McAdam LLC

McAdam LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,590 shares of the company’s stock after buying an additional 84 shares during the period. McAdam LLC’s holdings in Eli Lilly and Company were worth $927,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in Eli Lilly and Company by 0.9% in the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares during the period. Morgan Stanley increased its holdings in shares of Eli Lilly and Company by 0.7% in the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after acquiring an additional 83,915 shares during the period. Northern Trust Corp lifted its position in Eli Lilly and Company by 3.6% in the 3rd quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the last quarter. International Assets Investment Management LLC lifted its position in Eli Lilly and Company by 61,268.8% in the 4th quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in Eli Lilly and Company by 2.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after purchasing an additional 88,016 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the company’s stock in a transaction on Wednesday, January 31st. The stock was sold at an average price of $648.07, for a total transaction of $50,920,804.11. Following the transaction, the insider now directly owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $737.33 on Tuesday. The stock has a market capitalization of $700.58 billion, a P/E ratio of 127.13, a P/E/G ratio of 1.60 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. The business’s fifty day moving average is $760.89 and its two-hundred day moving average is $668.00. Eli Lilly and Company has a 1 year low of $392.26 and a 1 year high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. During the same quarter last year, the business posted $2.09 EPS. Eli Lilly and Company’s revenue was up 28.1% on a year-over-year basis. On average, research analysts forecast that Eli Lilly and Company will post 12.51 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on LLY shares. Citigroup lifted their price target on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Eli Lilly and Company from $775.00 to $850.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Three analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.